The temporal patterns of ICI-related endocrine toxicities exhibit class-specific characteristics: while PD-1 inhibitor-associated endocrinopathies typically emerge between weeks 10–24, CTLA-4 inhibitor-induced hypophysitis may manifest earlier (weeks 7–8). This evidence concerns the gene CTLA4 and hypophysitis.